• Home
  • Target Market
  • Pipeline
  • Our Team
  • Donate
  • Contact

 

slide1 slide2 slide3 slide3

Safe and Effective

ANP Cancer Drug

Lead drug compound KTH-222 Based on mechanisms used by the body to control cell growth

Treatment of Cancer

ANP Cancer Drug

First in Class drug places tumors into sustained non dividing state

Anti-Cancer Activity

ANP Cancer Drug

Safe non-toxic therapy NOT Chemo therapy

__________________________________________________________________________________________________________________________________________

The Company
Kalos is developing a groundbreaking approach to treating cancers and related co-morbidities. The Company’s revolutionary technology is based upon leveraging a natural, known mechanism in the body to regulate cell growth. This natural mechanism has been adapted by the Company’s researchers into a safe nontoxic therapeutic that has the potential to inhibit the growth of rapidly dividing human cancer cells and put them into a sustained non-dividing state. This first-in-class approach to treating cancer is believed to be safe when administered to patients based upon other peptides from this family that been already been administered to humans for the treatment of cardiovascular disorders. Kalos Therapeutics comprised of programs in three different disease areas. These three-program are built on the company’s intellectual property and knowledge embedded in a platform technology based on variations of this naturally occurring substance the body uses to control aberrant cell growth and regulate hemodynamics.

Anti Cancer Bio-technology

Kalos has successfully leveraged the natural antiproliferative activity of this family of peptides creating a new chemical entity in our patent pending Kalos Motif (s). This platform solidifies a never before seen anti-cancer approach which slows tumor growth and addresses severer comorbidities. This compound contains characteristics the body uses to also control hemodynamics and balancing that system to stay in homeostasis. Kalos has labored to identified the motif in this family of peptides that is responsible for controlling cell growth (the anti-cell proliferation motif, or ACM), and is developing a new class of anti-proliferative drugs based on this motifs multi-receptor activities.

__________________________________________________________________________________________________________________________________________


Kalos Therapeutics is developing peptides with broad spectrum anti tumor activity and a NON-TOXIC side effect profile

© Copyright Kalos Therapeutics. All Rights Reserved.   Powered By CellMark Biopharma™ | Privacy Policy | Make a Donation